Alterity Therapeutics Limited (NASDAQ:ATHE) Sees Large Drop in Short Interest

Alterity Therapeutics Limited (NASDAQ:ATHE) was the target of a large decline in short interest in November. As of November 30th, there was short interest totalling 2,000 shares, a decline of 45.9% from the November 15th total of 3,700 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 42,700 shares, the days-to-cover ratio is currently 0.0 days.

Alterity Therapeutics Price Performance

NASDAQ ATHE traded up $0.18 during midday trading on Friday, hitting $2.40. The company had a trading volume of 44,028 shares, compared to its average volume of 50,530. The firm has a 50-day moving average price of $1.36 and a 200-day moving average price of $1.51. Alterity Therapeutics has a twelve month low of $1.00 and a twelve month high of $3.25.

Analyst Upgrades and Downgrades

Separately, Maxim Group began coverage on shares of Alterity Therapeutics in a research report on Thursday. They set a “buy” rating and a $8.00 target price on the stock.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.